DRKS00025530CompletedPhase 4
My7steps App Trial Study - M7SA-TS
My7steps GmbH0 sites253 target enrollmentStarted: June 9, 2023Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Sponsor
- Enrollment
- 253
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized controlled study
- Masking
- Blinded (masking used)
Eligibility Criteria
- Ages
- 18 Years to 65 Years (—)
- Sex
- All
Inclusion Criteria
- •1. There is legal consent to participate
- •2. The ability to speak and understand German, English or Farsi/Dari
- •3. Between 18 and 65 years old
- •4. Living in Germany
- •5. Diagnosis of any of the following ICD-10 indications: F32.0, F32.1, F33.0, F33.1
Exclusion Criteria
- •Affected persons who do not meet the inclusion criteria are to be excluded from the study. In addition, people who meet the following criteria are excluded:
- •1. There has been a change in medication within the last 4 weeks
- •2. Participates in other interventional studies
- •3. Is in a dependent or employment relationship with the sponsor or investigator
- •4. Is housed in an institution due to a court or official order
- •5. Suicidal tendencies, diagnosed severe depression, addiction, psychotic symptoms or organic brain disorders (e.g. delirium, dementia) are present
Investigators
Similar Trials
Completed
Phase 4
My7steps App Pilot StudyF32.0F32.1F33.0F33.1F43.2Mild depressive episodeModerate depressive episodeRecurrent depressive disorder, current episode mildRecurrent depressive disorder, current episode moderateAdjustment disordersDRKS00027925Ipso Healthcare GmbH89
Recruiting
Not Applicable
TRAILS - Seventh assessment wave TRAILS-CClichamelijke gezondheidsproblemen, zoals pijn of astma(mental) health and social development1003717610024450NL-OMON54717niversitair Medisch Centrum Groningen
Active, not recruiting
Phase 1
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)ower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)MedDRA version: 20.0Level: HLTClassification code 10028536Term: Myelodysplastic syndromesSystem Organ Class: 100000004851MedDRA version: 27.0Level: PTClassification code 10028533Term: Myelodysplastic syndromeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-003281-40-BETaiho Oncology, Inc.128
Active, not recruiting
Phase 1
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)ower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)MedDRA version: 20.0Level: HLTClassification code 10028536Term: Myelodysplastic syndromesSystem Organ Class: 100000004851MedDRA version: 21.1Level: PTClassification code 10028533Term: Myelodysplastic syndromeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-003281-40-ESAstex Pharmaceuticals, Inc.168
Active, not recruiting
Phase 1
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)ower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)MedDRA version: 20.0Level: HLTClassification code 10028536Term: Myelodysplastic syndromesSystem Organ Class: 100000004851MedDRA version: 27.0Level: PTClassification code 10028533Term: Myelodysplastic syndromeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-003281-40-DETaiho Oncology, Inc.168